Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito
Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito
View: Text | PDF
Research Article Hepatology Virology

Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

  • Text
  • PDF
Abstract

Hepatitis delta virus (HDV), a satellite virus of HBV, is regarded as the most severe type of hepatitis virus because of the substantial morbidity and mortality. The IFN system is the first line of defense against viral infections and an essential element of antiviral immunity; however, the role of the hepatic IFN system in controlling HBV-HDV infection remains poorly understood. Herein, we showed that HDV infection of human hepatocytes induced a potent and persistent activation of the IFN system whereas HBV was inert in triggering hepatic antiviral response. Moreover, we demonstrated that HDV-induced constitutive activation of the hepatic IFN system resulted in a potent suppression of HBV while modestly inhibiting HDV. Thus, these pathogens are equipped with distinctive immunogenicity and varying sensitivity to the antiviral effectors of IFN, leading to the establishment of a paradoxical mode of viral interference wherein HDV, the superinfectant, outcompetes HBV, the primary pathogen. Furthermore, our study revealed that HDV-induced constitutive IFN system activation led to a state of IFN refractoriness, rendering therapeutic IFNs ineffective. The present study provides potentially novel insights into the role of the hepatic IFN system in regulating HBV-HDV infection dynamics and its therapeutic implications through elucidating the molecular basis underlying the inefficacy of IFN-based antiviral strategies against HBV-HDV infection.

Authors

Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito

×

Figure 5

HDV infection induces the state of IFN refractoriness in hepatocytes in vivo.

Options: View larger image (or click on image) Download as PowerPoint
HDV infection induces the state of IFN refractoriness in hepatocytes in ...
(A–E) HLCM (n = 40) were first infected with either mock (n = 12) or HBV (n = 28) for 7 weeks. HLCM infected with HBV (n = 28) were then superinfected with mock (n = 12; HBV mono-infection) or HDV (n = 16; HBV-HDV superinfection) for an additional 5 weeks. Blood samples of each animal at indicated time points were subjected to the quantification of HBV DNA and HDV RNA via RT-qPCR (A). (B–E) HLCM infected with mock, HBV, or HBV-HDV were administered with PBS or PEG–IFN-α-2a, which were killed for sampling as outlined in Supplemental Figure 5 for comparative analysis. Representative results of immunoblotting analysis (B) and RT-qPCR array analysis (C) of the liver tissue, harvested 24 hours after PBS or PEG–IFN-α-2a administration. Representative IFA image of the liver tissue (D) as well as RT-qPCR analysis of blood samples (E) harvested 7 days after PBS or PEG–IFN-α-2a administration. **P < 0.05 determined by unpaired 2-tailed Student’s t test. Error bars, SD. Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts